16. Net Loss Per Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method.

For the years ended December 31, 2019 and 2018, all of the Company’s common stock options, unvested restricted stock units and warrants are anti-dilutive and therefore have been excluded from the diluted calculation.

The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.:


	For the years ended
	December 31,
	2019		2018
Net loss	$	(20,384,716)	$	(16,591,293)
Net loss - Non-controlling interest		(367,148)		(857,439)
Net loss attributable to Heat Biologics, Inc.	$	(20,017,568)	$	(15,733,854)

Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted		33,281,817		17,485,461
Net loss per share attributable to Heat Biologics, Inc —basic and diluted	$	(0.60)	$	(0.90)

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:


	For the years ended
	December 31,
	2019	2018
Outstanding stock options	3,063,636	465,303
Restricted stock subject to forfeiture and restricted stock units	1,284,679	56,520
Outstanding common stock warrants	9,030,730	9,030,730